We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Shield Therapeutics plc (STX) Ordinary Shares 1.5p

Sell:1.45p Buy:1.50p 0 Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1.45p
Buy:1.50p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:1.45p
Buy:1.50p
Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company is focused on the commercialization of its oral iron therapy for iron deficiency. The Company's lead product, Feraccru/Accrufer (ferric maltol), is a stable, non-salt-based oral therapy for adults with iron deficiency with or without anemia. Ferric maltol is approved in the United States, European Union, United Kingdom and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Shield Therapeutics (DE) GmbH, Shield TX (Switzerland) AG, Shield TX (UK) Limited and Shield Therapeutics Inc.

Contact details

Address:
3rd Fl
Baltic Business Quarters, Abbott's Hill
GATESHEAD
NE8 3D
United Kingdom
Telephone:
+44 (0191) 5118500
Website:
https://www.shieldtherapeutics.com/

Important dates

Future events
Final results 30 April 2024 30/04/24
Past events
Trading Announcement 21 February 2024 21/02/24
Interim results 28 September 2023 28/09/23
Trading Announcement 20 July 2023 20/07/23
AGM 28 June 2023 28/06/23
Annual report 19 May 2023 19/05/23
Final results 27 April 2023 27/04/23

General stock information

EPIC:
STX
ISIN:
GB00BYV81293
Market cap:
£11.54 million
Shares in issue:
782.06 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Gregory Madison
    Chief Executive Officer, Executive Director
  • Santosh Shanbhag
    Chief Financial Officer
  • David Childs
    Vice President - Commercial Operations
  • Jackie Mitchell
    Vice President - Regulatory Affairs and Quality
  • Lucy Huntington-bailey
    General Counsel, Company Secretary
  • Andy Hurley
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.